The Life Sciences IPOs + Capital Markets team advised the underwriters of Freeline Therapeutics Holdings plc’s (Nasdaq: FRLN) initial public offering in the United States of 8,823,529 American Depositary Shares representing 8,823,529 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of approximately $158.8 million. In addition, Freeline has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 ADSs at the initial public offering price, less underwriting discounts and commissions.
Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases.
The Goodwin team was led by Mitch Bloom, Edwin O’Connor, Stephanie Richards and Kristen Armstrong, and included Duncan Greenhalgh, Megan Gustafson, Yingying Cai, Julie Tibbets, Steven Tjoe, Roger Cohen, Nikhil Sethi, Dan Karelitz, Robert Young, Ben Gossels, Andrew Harrow, Jacqueline Klosek, Sarah Bock, Andre Amorim, and Ettore Santucci, with invaluable assistance from Marishka DeToy and Kaitlin Carragher.
For more details, read the articles in Endpoints, Xconomy, and Seeking Alpha.